CY1120049T1 - (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i - Google Patents
(2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης iInfo
- Publication number
- CY1120049T1 CY1120049T1 CY20181100132T CY181100132T CY1120049T1 CY 1120049 T1 CY1120049 T1 CY 1120049T1 CY 20181100132 T CY20181100132 T CY 20181100132T CY 181100132 T CY181100132 T CY 181100132T CY 1120049 T1 CY1120049 T1 CY 1120049T1
- Authority
- CY
- Cyprus
- Prior art keywords
- oxazepan
- phenylethyl
- cyano
- carboxamide
- inhibitors
- Prior art date
Links
- NKLBVYYBRRBLAE-KBPBESRZSA-N (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=CC=C1)NC(=O)[C@H]1OCCCNC1 NKLBVYYBRRBLAE-KBPBESRZSA-N 0.000 title abstract 2
- KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 abstract 1
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 abstract 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 abstract 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931090P | 2014-01-24 | 2014-01-24 | |
| PCT/GB2015/050155 WO2015110826A1 (en) | 2014-01-24 | 2015-01-23 | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120049T1 true CY1120049T1 (el) | 2018-12-12 |
Family
ID=52432834
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100132T CY1120049T1 (el) | 2014-01-24 | 2018-02-05 | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i |
| CY20201100674T CY1123391T1 (el) | 2014-01-24 | 2020-07-23 | (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100674T CY1123391T1 (el) | 2014-01-24 | 2020-07-23 | (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι |
Country Status (39)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (cg-RX-API-DMAC7.html) | 2014-01-24 | 2018-02-24 | ||
| JP2019522039A (ja) * | 2016-07-29 | 2019-08-08 | インスメッド インコーポレイテッド | 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド |
| WO2019157050A1 (en) * | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
| ES3011730T3 (en) * | 2018-03-01 | 2025-04-08 | Astrazeneca Ab | Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
| EP3823627A4 (en) * | 2018-07-17 | 2022-04-20 | Insmed Incorporated | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY |
| AU2019305565A1 (en) * | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)- N-[(1A)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease |
| CN111689923B (zh) * | 2019-03-12 | 2022-11-08 | 中国科学院上海药物研究所 | 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途 |
| AU2020370210A1 (en) * | 2019-10-23 | 2022-04-21 | Chong Kun Dang Pharmaceutical Corp. | Compositions for preventing or treating chronic obstructive pulmonary diseases (COPD) |
| CA3181285A1 (en) | 2020-07-20 | 2022-01-27 | Jessica BASSO | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
| HRP20241656T1 (hr) | 2020-08-26 | 2025-02-14 | Haisco Pharmaceuticals Pte. Ltd. | Derivat nitrila koji djeluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CN114159446A (zh) * | 2020-09-11 | 2022-03-11 | 中国科学院上海营养与健康研究所 | 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用 |
| AU2021391452A1 (en) | 2020-12-04 | 2023-06-29 | Reistone Biopharma Company Limited | Small molecule inhibitor of cathepsin c and medicinal use thereof |
| CN114591315A (zh) * | 2020-12-04 | 2022-06-07 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂 |
| WO2022140516A1 (en) * | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
| CA3207466A1 (en) * | 2021-02-05 | 2022-08-11 | Lingyun Wu | Fused ring derivatives containing 1,4-oxazepane |
| EP4329767A4 (en) * | 2021-04-29 | 2025-03-12 | Insmed Incorporated | CERTAIN (1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF CYSTIC FIBROSIS |
| CN115925696A (zh) * | 2021-10-29 | 2023-04-07 | 瑞石生物医药有限公司 | 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途 |
| MX2024005126A (es) * | 2021-10-29 | 2024-05-16 | Insmed Inc | Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la rinosinusitis cronica. |
| CN116332937A (zh) * | 2021-12-23 | 2023-06-27 | 杭州邦顺制药有限公司 | 二肽基肽酶ⅰ抑制剂及其用途 |
| WO2023134656A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海壹典医药科技开发有限公司 | 一种肽基腈类化合物及其应用 |
| JP2025508359A (ja) * | 2022-02-16 | 2025-03-26 | インスメッド インコーポレイテッド | 化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド |
| AU2023224769A1 (en) * | 2022-02-22 | 2024-08-29 | Haisco Pharmaceuticals Pte. Ltd. | Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor |
| CA3243683A1 (en) * | 2022-02-22 | 2025-01-22 | Haisco Pharmaceuticals Pte. Ltd. | SALT AND CRYSTALLINE FORM OF DIPEPTIDYLPEPTIDASE INHIBITOR COMPOUND |
| JP2025506307A (ja) * | 2022-02-22 | 2025-03-07 | ハイスコ ファーマスーティカル プライベート リミテッド | 含窒素複素環化合物の調製方法 |
| CN114644562B (zh) * | 2022-04-29 | 2023-08-22 | 常州大学 | 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用 |
| KR20250020509A (ko) * | 2022-06-07 | 2025-02-11 | 레이스톤 바이오파마 컴퍼니 리미티드 | 벤조[c]크로만 화합물의 다형체, 이의 제조 방법 및 이의 용도 |
| CA3255979A1 (en) * | 2022-06-07 | 2025-03-18 | Reistone Biopharma Company Limited | PHARMACEUTICALLY ACCEPTABLE SALT OF A BENZO[C]CHROMANE COMPOUND, POLYMORPHIC FORM AND USE OF A PHARMACEUTICALLY ACCEPTABLE SALT |
| AU2023296161A1 (en) | 2022-06-13 | 2025-01-02 | Alivexis, Inc. | Azacycloalkyl carbonyl cyclic amine compound |
| EP4551554A1 (en) | 2022-07-06 | 2025-05-14 | Chiesi Farmaceutici S.p.A. | Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors |
| WO2024081889A1 (en) | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
| WO2024088307A1 (zh) * | 2022-10-26 | 2024-05-02 | 上海壹迪生物技术有限公司 | 一种新型肽基腈类化合物及其应用 |
| CN115785083A (zh) * | 2022-12-27 | 2023-03-14 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂及其制备方法 |
| WO2024148308A1 (en) * | 2023-01-06 | 2024-07-11 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2024173556A2 (en) * | 2023-02-15 | 2024-08-22 | Insmed Incorporated | Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors |
| WO2024193695A1 (zh) * | 2023-03-23 | 2024-09-26 | 西藏海思科制药有限公司 | 一种二肽基肽酶小分子抑制剂的药物组合物 |
| WO2025059526A1 (en) * | 2023-09-15 | 2025-03-20 | Insmed Incorporated | Dipeptidyl peptidase 1 inhibitors and uses thereof |
| USD1099133S1 (en) * | 2024-02-01 | 2025-10-21 | Apple Inc. | Display screen or portion thereof showing a graphical user interface |
| WO2025214073A1 (en) * | 2024-04-12 | 2025-10-16 | Insmed Incorporated | Dipeptidyl peptidase 1 inhibitors and uses thereof |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2782151B2 (ja) | 1993-07-16 | 1998-07-30 | 博 吉田 | 衝撃吸収柵用の端ストッパ |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6462076B2 (en) | 2000-06-14 | 2002-10-08 | Hoffmann-La Roche Inc. | Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
| EP1317555B1 (en) | 2000-09-08 | 2007-11-14 | Prozymex A/S | Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses |
| AU2001294196B2 (en) * | 2000-10-06 | 2005-11-17 | Tanabe Seiyaku Co., Ltd. | Nitrogenous five-membered ring compounds |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| ATE357432T1 (de) | 2001-12-04 | 2007-04-15 | Hoffmann La Roche | Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren |
| US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| ATE399763T1 (de) | 2003-05-30 | 2008-07-15 | Prozymex As | Proteasehemmer |
| WO2004110988A1 (en) | 2003-06-18 | 2004-12-23 | Prozymex A/S | Protease inhibitors |
| DK2206728T3 (en) | 2004-04-07 | 2018-04-23 | Rinat Neuroscience Corp | METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY |
| EP1745292A2 (en) | 2004-04-28 | 2007-01-24 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1) |
| US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| SE0401657D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| PL1916994T3 (pl) | 2004-06-29 | 2014-05-30 | Takeda Pharma As | Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku |
| WO2006020145A2 (en) | 2004-07-19 | 2006-02-23 | The Johns Hopkins University | Flt3 inhibitors for immune suppression |
| SI2301531T1 (sl) | 2005-02-18 | 2018-11-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| JP2009500347A (ja) | 2005-06-30 | 2009-01-08 | アムジエン・インコーポレーテツド | ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用 |
| MX2009009540A (es) | 2007-03-07 | 2009-09-16 | Alantos Pharm Holding | Inhibidores de metaloproteasa que contienen una porcion heterociclica. |
| WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
| AU2008305591A1 (en) | 2007-09-25 | 2009-04-02 | Nektar Therapeutics | Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin |
| WO2009074829A1 (en) | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| UY31867A (es) | 2008-06-06 | 2010-01-29 | Boehringer Ingelheim Int | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 |
| KR101805754B1 (ko) | 2008-12-08 | 2017-12-07 | 먼디파머 인터내셔널 코포레이션 리미티드 | 단백질 수용체 티로신 키나아제 억제제의 조성물 |
| CA2757418C (en) | 2009-04-01 | 2021-06-15 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
| CN102574830A (zh) | 2009-05-07 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 取代的1-氰基乙基杂环基甲酰胺化合物750 |
| WO2010142985A1 (en) * | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
| WO2011154677A1 (en) * | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
| IT1404036B1 (it) | 2010-12-17 | 2013-11-08 | Oto Melara Spa | Veicolo armato con struttura migliorata. |
| BR112013020510A2 (pt) | 2011-02-11 | 2016-07-12 | Glaxosmithkline Ip Dev Ltd | inibidores de catepsina c |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| AU2013224421B2 (en) | 2012-02-21 | 2017-03-02 | Merck Patent Gmbh | 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors |
| WO2013157562A1 (ja) | 2012-04-17 | 2013-10-24 | アステラス製薬株式会社 | 含窒素二環式芳香族へテロ環化合物 |
| WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| EP2775304A1 (en) | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
| US8877775B2 (en) | 2013-03-14 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C |
| US8889708B2 (en) | 2013-03-14 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C |
| JP6441830B2 (ja) | 2013-03-14 | 2018-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤 |
| GEP201706780B (en) | 2013-03-14 | 2017-11-27 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| KR20150135328A (ko) | 2013-04-01 | 2015-12-02 | 풀매트릭스 인코퍼레이티드 | 티오트로피움 건조 분말 |
| WO2015027039A1 (en) | 2013-08-22 | 2015-02-26 | Emory University | Devices and methods related to airway inflammation |
| WO2015032942A1 (en) | 2013-09-09 | 2015-03-12 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
| EA029030B1 (ru) | 2013-09-09 | 2018-01-31 | Прозюмекс А/С | Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (cg-RX-API-DMAC7.html) | 2014-01-24 | 2018-02-24 | ||
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| SG11201607894RA (en) | 2014-04-10 | 2016-10-28 | Novartis Ag | S1p modulator immediate release dosage regimen |
| KR20240018675A (ko) | 2014-05-15 | 2024-02-13 | 인스메드 인코포레이티드 | 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법 |
| CN107075557B (zh) | 2014-05-30 | 2021-07-06 | 香港大学 | 使用嗜中性粒细胞弹性蛋白酶和蛋白酶3作为诊断生物标志物的方法和组合物 |
| WO2016016242A1 (en) | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim International Gmbh | Substituted oxetanes and their use as inhibitors of cathepsin c |
| CN107074870B (zh) | 2014-09-12 | 2019-07-12 | 勃林格殷格翰国际有限公司 | 组织蛋白酶c的螺环化合物抑制剂 |
| AU2015345070A1 (en) | 2014-11-14 | 2017-04-20 | Boehringer Ingelheim International Gmbh | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists |
| DK3265452T3 (en) | 2015-03-05 | 2020-06-08 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| JP2019522039A (ja) | 2016-07-29 | 2019-08-08 | インスメッド インコーポレイテッド | 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド |
| WO2019157050A1 (en) | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
| ES3011730T3 (en) | 2018-03-01 | 2025-04-08 | Astrazeneca Ab | Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
| AU2019305565A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)- N-[(1A)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease |
| EP3823627A4 (en) | 2018-07-17 | 2022-04-20 | Insmed Incorporated | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY |
| WO2020214855A1 (en) | 2019-04-17 | 2020-10-22 | Azora Therapeutics, Inc. | Topical compositions and methods for treating inflammatory skin diseases |
| CA3139977A1 (en) | 2019-06-05 | 2020-12-10 | Raymond F. Schinazi | Peptidomimetics for the treatment of coronavirus and picornavirus infections |
| WO2022140516A1 (en) | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
| CN112920124B (zh) | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
| EP4329767A4 (en) | 2021-04-29 | 2025-03-12 | Insmed Incorporated | CERTAIN (1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF CYSTIC FIBROSIS |
| WO2022232420A1 (en) | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer |
| MX2024005126A (es) | 2021-10-29 | 2024-05-16 | Insmed Inc | Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la rinosinusitis cronica. |
| JP2025508359A (ja) | 2022-02-16 | 2025-03-26 | インスメッド インコーポレイテッド | 化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド |
-
2012
- 2012-04-15 NO NO12774761A patent/NO2699580T3/no unknown
-
2015
- 2015-01-21 US US14/601,371 patent/US9522894B2/en active Active
- 2015-01-23 RS RS20180069A patent/RS56919B1/sr unknown
- 2015-01-23 DK DK17195612.1T patent/DK3323814T3/da active
- 2015-01-23 SI SI201531287T patent/SI3323814T1/sl unknown
- 2015-01-23 BR BR112016016224-2A patent/BR112016016224B1/pt active IP Right Grant
- 2015-01-23 AU AU2015208932A patent/AU2015208932C1/en active Active
- 2015-01-23 SG SG10201701056QA patent/SG10201701056QA/en unknown
- 2015-01-23 CN CN201910716882.4A patent/CN110483492B/zh active Active
- 2015-01-23 KR KR1020167022665A patent/KR102417684B1/ko active Active
- 2015-01-23 EP EP25150988.1A patent/EP4548972A3/en active Pending
- 2015-01-23 ES ES20173862T patent/ES3018635T3/es active Active
- 2015-01-23 SM SM20180058T patent/SMT201800058T1/it unknown
- 2015-01-23 PE PE2016001236A patent/PE20161218A1/es unknown
- 2015-01-23 FI FIEP20173862.2T patent/FI3744714T3/fi active
- 2015-01-23 PT PT157015777T patent/PT3097086T/pt unknown
- 2015-01-23 AP AP2016009322A patent/AP2016009322A0/en unknown
- 2015-01-23 NZ NZ734768A patent/NZ734768A/en unknown
- 2015-01-23 HR HRP20250302TT patent/HRP20250302T1/hr unknown
- 2015-01-23 PT PT171956121T patent/PT3323814T/pt unknown
- 2015-01-23 PL PL15701577T patent/PL3097086T3/pl unknown
- 2015-01-23 EP EP17195612.1A patent/EP3323814B1/en active Active
- 2015-01-23 HK HK16114117.1A patent/HK1225730B/en unknown
- 2015-01-23 MY MYPI2016702657A patent/MY194850A/en unknown
- 2015-01-23 RS RS20200858A patent/RS60639B1/sr unknown
- 2015-01-23 SM SM20250137T patent/SMT202500137T1/it unknown
- 2015-01-23 LT LTEP15701577.7T patent/LT3097086T/lt unknown
- 2015-01-23 EP EP15701577.7A patent/EP3097086B1/en active Active
- 2015-01-23 UY UY0001035963A patent/UY35963A/es not_active Application Discontinuation
- 2015-01-23 JP JP2016548068A patent/JP6469711B2/ja active Active
- 2015-01-23 PT PT201738622T patent/PT3744714T/pt unknown
- 2015-01-23 SM SM20200433T patent/SMT202000433T1/it unknown
- 2015-01-23 CR CR20160327A patent/CR20160327A/es unknown
- 2015-01-23 ES ES15701577.7T patent/ES2658516T3/es active Active
- 2015-01-23 HU HUE17195612A patent/HUE052421T2/hu unknown
- 2015-01-23 EP EP20173862.2A patent/EP3744714B1/en active Active
- 2015-01-23 PL PL17195612T patent/PL3323814T3/pl unknown
- 2015-01-23 SI SI201530170T patent/SI3097086T1/en unknown
- 2015-01-23 EA EA201691375A patent/EA032794B1/ru unknown
- 2015-01-23 TW TW104102345A patent/TWI690517B/zh active
- 2015-01-23 NZ NZ722063A patent/NZ722063A/en unknown
- 2015-01-23 DK DK20173862.2T patent/DK3744714T3/da active
- 2015-01-23 LT LTEP17195612.1T patent/LT3323814T/lt unknown
- 2015-01-23 CN CN201580005484.1A patent/CN105980367B/zh active Active
- 2015-01-23 CA CA2935625A patent/CA2935625C/en active Active
- 2015-01-23 SG SG11201606052TA patent/SG11201606052TA/en unknown
- 2015-01-23 ES ES17195612T patent/ES2808060T3/es active Active
- 2015-01-23 WO PCT/GB2015/050155 patent/WO2015110826A1/en not_active Ceased
- 2015-01-23 MX MX2016009349A patent/MX368840B/es active IP Right Grant
- 2015-01-23 SI SI201532060T patent/SI3744714T1/sl unknown
- 2015-01-23 AR ARP150100202A patent/AR099177A1/es active IP Right Grant
- 2015-01-23 LT LTEP20173862.2T patent/LT3744714T/lt unknown
- 2015-01-23 HU HUE15701577A patent/HUE038274T2/hu unknown
- 2015-01-23 PL PL20173862.2T patent/PL3744714T3/pl unknown
- 2015-01-23 HU HUE20173862A patent/HUE070606T2/hu unknown
- 2015-01-23 HR HRP20180116TT patent/HRP20180116T1/hr unknown
- 2015-01-23 RS RS20250323A patent/RS66709B1/sr unknown
- 2015-01-23 DK DK15701577.7T patent/DK3097086T3/en active
-
2016
- 2016-07-05 IL IL246614A patent/IL246614B/en active IP Right Grant
- 2016-07-13 DO DO2016000175A patent/DOP2016000175A/es unknown
- 2016-07-20 PH PH12016501439A patent/PH12016501439A1/en unknown
- 2016-07-25 CL CL2016001889A patent/CL2016001889A1/es unknown
- 2016-08-23 ZA ZA2016/05856A patent/ZA201605856B/en unknown
- 2016-11-08 US US15/346,411 patent/US9815805B2/en active Active
-
2017
- 2017-01-18 AU AU2017200338A patent/AU2017200338B2/en active Active
- 2017-06-11 IL IL252836A patent/IL252836A0/en active IP Right Grant
- 2017-09-19 US US15/708,634 patent/US10287258B2/en active Active
-
2018
- 2018-01-22 ZA ZA2018/00431A patent/ZA201800431B/en unknown
- 2018-02-05 CY CY20181100132T patent/CY1120049T1/el unknown
- 2018-04-30 AU AU2018202956A patent/AU2018202956B2/en active Active
-
2019
- 2019-01-16 JP JP2019005300A patent/JP6804570B2/ja active Active
- 2019-03-19 US US16/358,091 patent/US10669245B2/en active Active
- 2019-03-25 IL IL265611A patent/IL265611A/en unknown
- 2019-04-17 AU AU2019202675A patent/AU2019202675B2/en active Active
-
2020
- 2020-04-22 US US16/855,522 patent/US11117874B2/en active Active
- 2020-07-23 CY CY20201100674T patent/CY1123391T1/el unknown
- 2020-07-23 HR HRP20201147TT patent/HRP20201147T1/hr unknown
- 2020-12-02 JP JP2020200413A patent/JP7157791B2/ja active Active
-
2021
- 2021-02-08 US US17/170,641 patent/US11667615B2/en active Active
-
2022
- 2022-04-04 JP JP2022062548A patent/JP7336563B2/ja active Active
- 2022-09-09 US US17/942,106 patent/US11655221B2/en active Active
- 2022-09-09 US US17/942,111 patent/US11773069B2/en active Active
- 2022-09-10 US US17/942,121 patent/US11655223B2/en active Active
- 2022-09-10 US US17/942,120 patent/US11655222B2/en active Active
- 2022-09-10 US US17/942,122 patent/US11655224B2/en active Active
- 2022-09-10 US US17/942,112 patent/US11673871B2/en active Active
- 2022-09-10 US US17/942,123 patent/US11814359B2/en active Active
- 2022-09-15 US US17/946,024 patent/US11680049B2/en active Active
- 2022-09-16 US US17/946,112 patent/US11673872B2/en active Active
-
2023
- 2023-04-13 US US18/300,350 patent/US20230250071A1/en not_active Abandoned
- 2023-08-21 JP JP2023133935A patent/JP7628587B2/ja active Active
- 2023-12-08 US US18/533,894 patent/US12054465B2/en active Active
-
2024
- 2024-06-17 US US18/745,710 patent/US20240336582A1/en not_active Abandoned
-
2025
- 2025-01-29 JP JP2025012602A patent/JP7714823B2/ja active Active
- 2025-07-16 JP JP2025119347A patent/JP2025157389A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| MX387125B (es) | Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. | |
| EA201590457A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
| EA201591371A1 (ru) | Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| EA201690888A1 (ru) | Новые гетероциклические соединения | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201791780A1 (ru) | Ингаляционный раствор тиотропия для небулайзерного распыления | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| EA201692276A1 (ru) | Комбинации тиотропия бромида, формотерола и будесонида для лечения хобл | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний |